Beam Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Beam Therapeutics Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q2 2024.
  • Beam Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $31.6M, a 20.3% increase year-over-year.
  • Beam Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $109M, a 15.2% increase year-over-year.
  • Beam Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $98.6M, a 17% increase from 2022.
  • Beam Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $84.3M, a 93.5% increase from 2021.
  • Beam Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2021 was $43.6M, a 183% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $109M $31.6M +$5.33M +20.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $104M $29.3M +$5.36M +22.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $98.6M $22.6M +$118K +0.52% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $98.5M $25.8M +$3.63M +16.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $94.9M $26.3M +$4.7M +21.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $90.2M $23.9M +$5.88M +32.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $84.3M $22.5M +$7M +45.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $77.3M $22.2M +$9.24M +71.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $68.1M $21.6M +$11.1M +106% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $57M $18M +$13.4M +288% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $43.6M $15.5M +$8.7M +128% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $34.9M $13M +$9.96M +331% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $24.9M $10.5M +$7.68M +277% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $17.2M $4.65M +$1.86M +66.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $15.4M $6.81M +$4.75M +231% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $10.6M $3.01M +$983K +48.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $9.65M $2.77M +$696K +33.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $8.95M $2.79M +$1.92M +221% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 $7.03M $2.06M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $2.03M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $2.07M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $869K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.